Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer

Endocrine-Related Cancer

Volumn 18, Issue 2, 2011, Pages 207-219

  Rosenblatt, Adena E ^a   Garcia, Maria Ines ^a   Lyons, Leah ^b   Xie, Yingqiu ^a   Maiorino, Carol ^a   Désiré, Laurent ^c   Slingerland, Joyce ^a   Burnstein, Kerry L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c ExonHit Therapeutics   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EHT 1864; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; P21 ACTIVATED KINASE 1; PROTEIN INHIBITOR; PROTEIN VAV3; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DOWN REGULATION; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROMOTER REGION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ENZYME INHIBITORS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; P21-ACTIVATED KINASES; PROTO-ONCOGENE PROTEINS C-VAV; PYRONES; QUINOLINES; RAC1 GTP-BINDING PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO GTP-BINDING PROTEINS; RNA; TRANSCRIPTION, GENETIC;

EID: 79953224449     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0049     Document Type: Article

References (44)

1. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J & Kumar R 1998 Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. Journal of Biological Chemistry 273 28238-28246. (doi:10.1074/jbc.273.43.28238)
2. Ali S & Coombes RC 2002 Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews. Cancer 2 101-112. (doi:10.1038/nrc721)
3. Balasenthil S, Barnes CJ, Rayala SK & Kumar R 2004 Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Letters 567 243-247. (doi:10.1016/j.febslet.2004.04.071)
4. Baugher PJ, Krishnamoorthy L, Price JE & Dharmawardhane SF 2005 Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Research: BCR 7 R965-R974. (doi:10.1186/bcr1329)
5. Bosco EE, Mulloy JC & Zheng Y 2009 Rac1 GTPase: a "rac" of all trades. Cellular and Molecular Life Sciences: CMLS 66 370-374. (doi:10.1007/s00018-008-8552-x)
6. Burbelo P, Wellstein A & Pestell RG 2004 Altered rho GTPase signaling pathways in breast cancer cells. Breast Cancer Research and Treatment 84 43-48. (doi:10.1023/B:BREA.0000018422.02237.f9)
7. Cai D, Iyer A, Felekkis KN, Near RI, Luo Z, Chernoff J, Albanese C, Pestell RG & Lerner A 2003 AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates rac, PAK1, and the cyclin D1 promoter. Cancer Research 63 6802-6808. (Pubitemid 37322962)
8. Chan AY, Coniglio SJ, Chuang YY, Michaelson D, Knaus UG, Philips MR & Symons M 2005 Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 24 7821-7829. (doi:10.1038/sj.onc.1208909)
9. Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK & Slingerland JM 2009 Combined src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 15 3396-3405. (doi:10.1158/1078-0432. CCR-08-3127)
10. Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jorda M, Ju Z, Hennessy BT & Slingerland JM 2010 Combined src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Research and Treatment [in press]. (doi:10.1007/s10549-010-1024-7)
11. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, Chun K, Hennessy B, Mills GB, Nawaz Z et al. 2007 Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. Journal of Clinical Investigation 117 2205-2215. (doi:10.1172/JCI21739)
12. deConinck EC, McPherson LA & Weigel RJ 1995 Transcriptional regulation of estrogen receptor in breast carcinomas. Molecular and Cellular Biology 15 2191-2196.
13. Dhananjayan SC, Ramamoorthy S, Khan OY, Ismail A, Sun J, Slingerland J, O'Malley BW & Nawaz Z 2006 WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Molecular Endocrinology 20 2343-2354. (doi:10.1210/me.2005-0533)
14. Fritz G, Brachetti C, Bahlmann F, Schmidt M & Kaina B 2002 Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. British Journal of Cancer 87 635-644. (doi:10.1038/sj.bjc.6600510)
15. Guo S & Sonenshein GE 2004 Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Molecular and Cellular Biology 24 8681-8690. (doi:10.1128/MCB.24.19.8681-8690.2004)
16. Hall A 1998 Rho GTPases and the actin cytoskeleton. Science 279 509-514. (doi:10.1126/science.279.5350.509)
17. Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES & Burnstein KL 2004 Deregulation of the rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene 23 5513-5522. (doi:10.1038/sj.onc.1207708)
18. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW & Span PN 2005 Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Laboratory Investigation; A Journal of Technical Methods and Pathology 85 154-159. (doi:10.1038/labinvest.3700208)
19. Lange CA 2004 Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Molecular Endocrinology 18 269-278. (doi:10.1210/me.2003-0331)
20. Lee H, Jiang F, Wang Q, Nicosia SV, Yang J, Su B & Bai W 2000 MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Molecular Endocrinology 14 1882-1896. (doi:10.1210/me.14.11.1882)
21. Lee AV, Cui X & Oesterreich S 2001 Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 7 4429s-4435s (discussion 4411s-4412s).
22. Lee K, Liu Y, Mo JQ, Zhang J, Dong Z & Lu S 2008 Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer 8 158. (doi:10.1186/1471-2407-8-158)
23. Lyons LS & Burnstein KL 2006 Vav3, a rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Molecular Endocrinology 20 1061-1072. (doi:10.1210/me.2005-0346)
24. Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA & Burnstein KL 2008 Ligand-independent activation of androgen receptors by rho GTPase signaling in prostate cancer. Molecular Endocrinology 22 597-608. (doi:10.1210/me.2007-0158)
25. Manser E, Leung T, Salihuddin H, Zhao ZS & Lim L 1994 A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367 40-46. (doi:10.1038/367040a0)
26. Masiello D, Cheng S, Bubley GJ, Lu ML & Balk SP 2002 Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. Journal of Biological Chemistry 277 26321-26326. (doi:10.1074/jbc.M203310200)
27. Mazumdar A & Kumar R 2003 Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Letters 535 6-10. (doi:10.1016/S0014- 5793(02)03846-2)
28. Onesto C, Shutes A, Picard V, Schweighoffer F & Der CJ 2008 Characterization of EHT 1864, a novel small molecule inhibitor of rac family small GTPases. Methods in Enzymology 439 111-129. (doi:10.1016/S0076-6879(07) 00409-0)
29. Rayala SK, Molli PR & Kumar R 2006a Nuclear p21- activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Research 66 5985-5988. (doi:10.1158/0008-5472.CAN-06-0978)
30. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, Aldaz CM, Khan S & Kumar R 2006b P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Research 66 1694-1701. (doi:10.1158/0008- 5472.CAN-05-2922)
31. Sahai E & Marshall CJ 2002 RHO-GTPases and cancer. Nature Reviews. Cancer 2 133-142. (doi:10.1038/nrc725)
32. Schiff R, Chamness GC & Brown PH 2003 Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Research: BCR 5 228-231. (doi:10.1186/bcr626)
33. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M & Osborne CK 2005 Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemotherapy and Pharmacology 56 (Supplement 1) 10-20. (doi:10.1007/s00280-005-0108-2)
34. Schmittgen TD & Livak KJ 2008 Analyzing real-time PCR data by the comparative CT method. Nature Protocols 3 1101-1108. (doi:10.1038/nprot.2008.73)
35. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M & Lengyel E 2000 Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19 3013-3020. (doi:10.1038/sj.onc.1203621)
36. Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F & Der CJ 2007 Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of rac family small GTPases. Journal of Biological Chemistry 282 35666-35678. (doi:10.1074/jbc.M703571200)
37. Su LF, Knoblauch R & Garabedian MJ 2001 Rho GTPases as modulators of the estrogen receptor transcriptional response. Journal of Biological Chemistry 276 3231-3237. (doi:10.1074/jbc.M005547200)
38. Sun J, Nawaz Z & Slingerland JM 2007 Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells. Molecular Endocrinology 21 2651-2662. (doi:10.1210/me.2007- 0082)
39. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, Chernoff J, Hung MC & Kumar R 2000 Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. Journal of Biological Chemistry 275 36238-36244. (doi:10.1074/jbc.M002138200)
40. Van Aelst L & D'Souza-Schorey C 1997 Rho GTPases and signaling networks. Genes and Development 11 2295-2322. (doi:10.1101/gad.11.18.2295)
41. Wang RA, Mazumdar A, Vadlamudi RK & Kumar R 2002 P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO Journal 21 5437-5447. (doi:10.1093/emboj/cdf543)
42. Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L, Pestell RG & Der CJ 1997 Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Molecular and Cellular Biology 17 1324-1335.
43. Xie JW & Haslam SZ 2008 Extracellular matrix, Rac1 signaling, and estrogen-induced proliferation in MCF-7 breast cancer cells. Breast Cancer Research and Treatment 110 257-268. (doi:10.1007/s10549-007-9719-0)
44. Yang C, Liu Y, Lemmon MA & Kazanietz MG 2006 Essential role for rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Molecular and Cellular Biology 26 831-842. (doi:10.1128/MCB.26.3.831-842.2006)